Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 0.78 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.50 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.47 |
| ▸ | MARK3 | P27448 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403591 | 0.93 | S1PR1 (0.90) | S1PR1S1PR3MAP4K4MINK1CYP2C9 | |
| SCHEMBL13261907 | 0.90 | S1PR1 (0.72) | S1PR1S1PR3MAP4K4MINK1CYP2C9 | |
| SCHEMBL459581 | 0.90 | S1PR1 (0.78) | S1PR1S1PR3MAP4K4MINK1CYP2C9 | |
| SCHEMBL401604 | 0.90 | S1PR1 (0.92) | S1PR1S1PR3MAP4K4MINK1CYP2C9 | |
| SCHEMBL404072 | 0.90 | S1PR1 (0.77) | S1PR1S1PR3MAP4K4MINK1CYP2C9 | |
| SCHEMBL398987 | 0.88 | S1PR1 (1.00) | S1PR1S1PR3MAP4K4MINK1CYP2C9 | |
| SCHEMBL404571 | 0.86 | S1PR1 (0.81) | S1PR1S1PR3MAP4K4MINK1CYP2C9 | |
| SCHEMBL404167 | 0.86 | S1PR1 (0.84) | S1PR1S1PR3MAP4K4MINK1CYP2C9 | |
| SCHEMBL14189656 | 0.84 | S1PR1 (0.73) | S1PR1S1PR3MAP4K4MINK1CYP2C9 | |
| SCHEMBL1843851 | 0.84 | S1PR1 (0.73) | S1PR1S1PR3MAP4K4MINK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206710-B1 | Indole derivatives as S1P1 receptor agonists | GLAXO GROUP LTD (GB) | 2012-07-04 | — | — | EP | disclosed |
| US-8101775-B2 | Indole derivatives as S1P1 Receptor | GLAXO GROUP LIMITED (GB) | 2012-01-24 | — | — | US | disclosed |
| US-8101775-B2 | Indole derivatives as S1P1 Receptor | GLAXO GROUP LIMITED (GB) | 2012-01-24 | — | — | US | disclosed |
| US-8101775-B2 | Indole derivatives as S1P1 Receptor | GLAXO GROUP LIMITED (GB) | 2012-01-24 | — | — | US | disclosed |
| EP-2091949-B1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2011-05-18 | — | — | EP | disclosed |
| EP-2206710-A1 | Indole derivatives as S1P1 receptor agonists | Glaxo Group Limited (GB) | 2010-07-14 | — | — | EP | disclosed |
| US-20100113796-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | disclosed |
| US-20100113796-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | disclosed |
| US-20100113796-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | disclosed |
| WO-2008074821-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113796-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885MAP4K4 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.